Stock Updates

How has BioMarin Pharmaceutical Inc.:(NASDAQ:BMRN) performed recently?

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a large market cap stock with a market cap of 17263.04. It is in the Biotechnology industry and sector Healthcare, with a current P/E of *TBA, a forward P/E of *TBA and EPS of -3.27. At a stock price of 100.18 (0.76%) it has a dividend yield of *TBA.

EPS growth for the last five years have been -21.30%, more recently this last year it has grown by -17.30%. The next year growth is going to be about 73.00% and more long-term 25.00% after five years. EPS growth quarter over quarter is -154.80%. Sales growth for the past five years have been 18.80% and sales growth quarter over quarter is -40.10%.

For performance, BioMarin Pharmaceutical Inc. the past week has seen a gain of 8.38%. For the last month performance for BioMarin Pharmaceutical Inc. is 7.16%. While the last quarter is 13.05% and half year, 30.25%. Finally for the year, performance is -21.19%.

The 52-week high for BioMarin Pharmaceutical Inc., is at -26.79%, and for the 52-week low it comes to a value of 61.28%. The 20-day simple moving average is 11.58% and 13.01% for the 200-day simple moving average.

Volatility for the week is at 2.65%, and for the month it is 3.09%. BioMarin Pharmaceutical Inc., has a target price of 119.29.

In terms of debt, long term debt/equity is 0.34, and for total debt/equity BioMarin Pharmaceutical Inc. has 0.35. The gross margin is 82.10%, while operating margin is -65.20%, the profit margin is -54.50%. The current ratio is 3 and the quick ratio is 2.1.

Insider ownership is at 0.60%, with instituitional ownership at 99.20%. BioMarin Pharmaceutical Inc. has a payout ratio of *TBA. With the total shares outstanding coming to 173.62. The shares float is 170.17, with the float short at 3.61%, with short ratio coming to 3.26.

In terms of returns, the return on assets see BioMarin Pharmaceutical Inc., get -15.10%, with its returns on investment at -4.20%. Return on equity is -23.90%. So will the investors see the target price of 119.29, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Stephen Butters

Leave a Comment